title: Fluorinated tracers for imaging cancer with positron emission tomography.
abstract: 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism.
authors.affiliation: Division of Nuclear Medicine, Hôtel Dieu, CHU, Nantes, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Couturier
authors.forename: André
authors.initials: A
authors.lastname: Luxen
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Chatal
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Vuillez
authors.forename: Pierre
authors.initials: P
authors.lastname: Rigo
authors.forename: Roland
authors.initials: R
authors.lastname: Hustinx
mesh_terms: D000596:Amino Acids; D000818:Animals; D005462:Fluorine Radioisotopes; D006801:Humans; D009369:Neoplasms / Q000378:metabolism*; D009705:Nucleosides; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013256:Steroids
chemical_list: D000596:Amino Acids; D005462:Fluorine Radioisotopes; D009705:Nucleosides; D019275:Radiopharmaceuticals; D013256:Steroids